Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Drug Eruptions | 12 | 2024 | 335 | 4.520 |
Why?
|
Skin Diseases | 14 | 2024 | 1095 | 4.020 |
Why?
|
Pemphigoid, Bullous | 6 | 2024 | 112 | 3.610 |
Why?
|
Exanthema | 10 | 2024 | 503 | 3.250 |
Why?
|
Stevens-Johnson Syndrome | 7 | 2024 | 246 | 3.050 |
Why?
|
Skin | 21 | 2024 | 4473 | 2.710 |
Why?
|
Neoplasms | 25 | 2024 | 22125 | 1.840 |
Why?
|
Dermatology | 13 | 2023 | 918 | 1.780 |
Why?
|
Immunotherapy | 16 | 2023 | 4642 | 1.460 |
Why?
|
Skin Neoplasms | 10 | 2024 | 5809 | 1.180 |
Why?
|
Administration, Cutaneous | 7 | 2023 | 713 | 1.060 |
Why?
|
Melanoma | 8 | 2023 | 5694 | 1.000 |
Why?
|
Pemphigoid Gestationis | 1 | 2024 | 5 | 0.960 |
Why?
|
Mycosis Fungoides | 3 | 2021 | 170 | 0.940 |
Why?
|
Xylazine | 1 | 2024 | 12 | 0.920 |
Why?
|
Colitis | 3 | 2020 | 1234 | 0.840 |
Why?
|
Vasculitis, Leukocytoclastic, Cutaneous | 1 | 2023 | 42 | 0.830 |
Why?
|
Skin Ulcer | 1 | 2024 | 130 | 0.820 |
Why?
|
Immunosuppressive Agents | 3 | 2024 | 4189 | 0.740 |
Why?
|
Professional Autonomy | 2 | 2019 | 171 | 0.700 |
Why?
|
Macrophages, Alveolar | 1 | 2022 | 410 | 0.690 |
Why?
|
Pemphigus | 1 | 2021 | 107 | 0.680 |
Why?
|
Lymphoma, Follicular | 1 | 2024 | 457 | 0.680 |
Why?
|
Necrosis | 1 | 2024 | 1611 | 0.660 |
Why?
|
Tuberculosis, Cutaneous | 1 | 2019 | 17 | 0.650 |
Why?
|
Skin Diseases, Vesiculobullous | 1 | 2020 | 85 | 0.650 |
Why?
|
Substance Abuse, Intravenous | 1 | 2024 | 529 | 0.650 |
Why?
|
Cryoglobulinemia | 1 | 2019 | 84 | 0.620 |
Why?
|
Vasculitis | 1 | 2023 | 522 | 0.620 |
Why?
|
Pemphigus, Benign Familial | 1 | 2018 | 8 | 0.610 |
Why?
|
Adrenal Cortex Hormones | 3 | 2022 | 1878 | 0.580 |
Why?
|
Lymphoma, B-Cell | 1 | 2023 | 938 | 0.550 |
Why?
|
Diuretics | 1 | 2020 | 611 | 0.540 |
Why?
|
Humans | 99 | 2024 | 761098 | 0.540 |
Why?
|
Leg Dermatoses | 1 | 2015 | 20 | 0.510 |
Why?
|
Naltrexone | 1 | 2018 | 317 | 0.500 |
Why?
|
Leg Ulcer | 1 | 2015 | 71 | 0.490 |
Why?
|
Placenta | 1 | 2024 | 1709 | 0.490 |
Why?
|
Anti-Bacterial Agents | 3 | 2024 | 7405 | 0.490 |
Why?
|
Methotrexate | 1 | 2021 | 1717 | 0.480 |
Why?
|
Immune Tolerance | 2 | 2020 | 2307 | 0.450 |
Why?
|
Retrospective Studies | 27 | 2024 | 80673 | 0.440 |
Why?
|
Drug Hypersensitivity | 1 | 2022 | 918 | 0.430 |
Why?
|
Narcotic Antagonists | 1 | 2018 | 585 | 0.420 |
Why?
|
Insurance Coverage | 1 | 2024 | 1937 | 0.420 |
Why?
|
Photochemotherapy | 1 | 2019 | 826 | 0.410 |
Why?
|
Biopsy | 6 | 2024 | 6781 | 0.410 |
Why?
|
Pharmaceutical Preparations | 1 | 2020 | 1086 | 0.390 |
Why?
|
Autoimmune Diseases | 1 | 2023 | 2243 | 0.370 |
Why?
|
Immunologic Factors | 1 | 2020 | 1589 | 0.370 |
Why?
|
Immunocompromised Host | 1 | 2016 | 858 | 0.370 |
Why?
|
Serine Proteinase Inhibitors | 1 | 2012 | 175 | 0.360 |
Why?
|
Aged | 29 | 2024 | 169266 | 0.350 |
Why?
|
Practice Guidelines as Topic | 5 | 2020 | 7400 | 0.350 |
Why?
|
Female | 41 | 2024 | 392458 | 0.330 |
Why?
|
Diet Therapy | 1 | 2010 | 151 | 0.330 |
Why?
|
Patients | 1 | 2015 | 906 | 0.320 |
Why?
|
Middle Aged | 31 | 2024 | 220835 | 0.320 |
Why?
|
Internship and Residency | 5 | 2023 | 5879 | 0.310 |
Why?
|
Hospitalization | 5 | 2024 | 10712 | 0.310 |
Why?
|
Patient Satisfaction | 2 | 2018 | 3450 | 0.310 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2018 | 1405 | 0.300 |
Why?
|
Male | 40 | 2024 | 360675 | 0.290 |
Why?
|
Lymph Nodes | 1 | 2019 | 3461 | 0.280 |
Why?
|
Gastric Bypass | 1 | 2015 | 818 | 0.270 |
Why?
|
Referral and Consultation | 1 | 2019 | 3603 | 0.270 |
Why?
|
Oligopeptides | 1 | 2012 | 1178 | 0.270 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 3 | 2021 | 5318 | 0.260 |
Why?
|
Diagnosis, Differential | 4 | 2024 | 12975 | 0.240 |
Why?
|
Healthcare Disparities | 1 | 2020 | 3352 | 0.240 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2018 | 4021 | 0.230 |
Why?
|
Immunoblastic Lymphadenopathy | 1 | 2024 | 40 | 0.230 |
Why?
|
Amoxicillin-Potassium Clavulanate Combination | 1 | 2024 | 33 | 0.230 |
Why?
|
Psoriasis | 2 | 2023 | 945 | 0.230 |
Why?
|
Radioimmunotherapy | 1 | 2024 | 91 | 0.230 |
Why?
|
Paraparesis, Tropical Spastic | 1 | 2023 | 32 | 0.220 |
Why?
|
Exudates and Transudates | 1 | 2024 | 174 | 0.220 |
Why?
|
Hepatitis C, Chronic | 1 | 2012 | 1027 | 0.220 |
Why?
|
Adult | 21 | 2024 | 221083 | 0.210 |
Why?
|
Liver | 1 | 2019 | 7513 | 0.210 |
Why?
|
Human T-lymphotropic virus 1 | 1 | 2023 | 142 | 0.210 |
Why?
|
Dapsone | 1 | 2023 | 56 | 0.210 |
Why?
|
Perineum | 1 | 2024 | 208 | 0.210 |
Why?
|
Lactate Dehydrogenases | 1 | 2022 | 26 | 0.200 |
Why?
|
Doxycycline | 1 | 2024 | 344 | 0.200 |
Why?
|
Lung Neoplasms | 3 | 2021 | 13382 | 0.200 |
Why?
|
Teaching Rounds | 2 | 2016 | 276 | 0.190 |
Why?
|
Anal Canal | 1 | 2024 | 374 | 0.190 |
Why?
|
Neoplasms, Second Primary | 2 | 2019 | 1051 | 0.190 |
Why?
|
Erythema | 1 | 2023 | 262 | 0.190 |
Why?
|
Antipruritics | 1 | 2020 | 31 | 0.180 |
Why?
|
Cross-Sectional Studies | 5 | 2024 | 26068 | 0.180 |
Why?
|
Granuloma | 1 | 2023 | 327 | 0.180 |
Why?
|
Langerhans Cells | 1 | 2021 | 170 | 0.180 |
Why?
|
Prognosis | 6 | 2021 | 29672 | 0.180 |
Why?
|
Aged, 80 and over | 8 | 2024 | 58946 | 0.170 |
Why?
|
Antiviral Agents | 1 | 2012 | 3048 | 0.160 |
Why?
|
Histiocytosis, Langerhans-Cell | 1 | 2021 | 169 | 0.160 |
Why?
|
Plasma Cells | 1 | 2023 | 597 | 0.160 |
Why?
|
Periodontitis | 1 | 2024 | 568 | 0.160 |
Why?
|
Competency-Based Education | 1 | 2020 | 222 | 0.160 |
Why?
|
Colitis, Microscopic | 1 | 2019 | 71 | 0.160 |
Why?
|
Antibodies, Monoclonal | 4 | 2023 | 9185 | 0.160 |
Why?
|
Budesonide | 1 | 2019 | 158 | 0.160 |
Why?
|
Coronavirus Infections | 3 | 2020 | 3094 | 0.150 |
Why?
|
Purpura | 1 | 2019 | 117 | 0.150 |
Why?
|
Pneumonia, Viral | 3 | 2020 | 3216 | 0.150 |
Why?
|
Abdomen | 1 | 2024 | 1128 | 0.150 |
Why?
|
Tumor Microenvironment | 2 | 2021 | 3869 | 0.150 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2024 | 12145 | 0.140 |
Why?
|
Immunity, Mucosal | 1 | 2021 | 484 | 0.140 |
Why?
|
Consensus | 2 | 2024 | 3133 | 0.140 |
Why?
|
Risk Assessment | 6 | 2021 | 24013 | 0.140 |
Why?
|
Polypharmacy | 1 | 2020 | 306 | 0.140 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2023 | 1089 | 0.140 |
Why?
|
Macrophages | 2 | 2022 | 5754 | 0.140 |
Why?
|
Shock, Cardiogenic | 1 | 2022 | 709 | 0.140 |
Why?
|
Outpatient Clinics, Hospital | 1 | 2019 | 392 | 0.140 |
Why?
|
Cyclosporine | 1 | 2019 | 776 | 0.130 |
Why?
|
Social Justice | 1 | 2020 | 477 | 0.130 |
Why?
|
Coronary Disease | 1 | 2010 | 5921 | 0.130 |
Why?
|
Delayed Diagnosis | 1 | 2020 | 465 | 0.130 |
Why?
|
Fibrosis | 1 | 2023 | 2051 | 0.130 |
Why?
|
Ligands | 1 | 2022 | 3266 | 0.120 |
Why?
|
Pain | 2 | 2024 | 5070 | 0.120 |
Why?
|
Sex Distribution | 2 | 2019 | 2278 | 0.120 |
Why?
|
Lymphoproliferative Disorders | 1 | 2019 | 530 | 0.120 |
Why?
|
Survival Rate | 2 | 2019 | 12727 | 0.120 |
Why?
|
Edema | 1 | 2019 | 765 | 0.120 |
Why?
|
Biological Specimen Banks | 1 | 2020 | 778 | 0.120 |
Why?
|
Cohort Studies | 8 | 2023 | 41486 | 0.120 |
Why?
|
Proportional Hazards Models | 3 | 2018 | 12467 | 0.110 |
Why?
|
Respiratory Insufficiency | 1 | 2023 | 1231 | 0.110 |
Why?
|
Communicable Disease Control | 1 | 2020 | 846 | 0.110 |
Why?
|
Keratinocytes | 1 | 2018 | 790 | 0.110 |
Why?
|
Sarcoidosis | 1 | 2019 | 537 | 0.110 |
Why?
|
Perception | 2 | 2019 | 1198 | 0.110 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2019 | 709 | 0.110 |
Why?
|
Monocytes | 1 | 2022 | 2570 | 0.110 |
Why?
|
Incidence | 4 | 2024 | 21357 | 0.110 |
Why?
|
Intestinal Mucosa | 2 | 2021 | 3030 | 0.100 |
Why?
|
Neurodegenerative Diseases | 1 | 2022 | 1085 | 0.100 |
Why?
|
Gastrointestinal Diseases | 1 | 2021 | 1201 | 0.100 |
Why?
|
Abdominal Pain | 1 | 2019 | 1071 | 0.100 |
Why?
|
Carcinoma, Basal Cell | 1 | 2018 | 557 | 0.100 |
Why?
|
Radiography, Thoracic | 1 | 2019 | 1303 | 0.100 |
Why?
|
Pandemics | 3 | 2020 | 8663 | 0.100 |
Why?
|
Endothelial Growth Factors | 1 | 2014 | 672 | 0.100 |
Why?
|
Fatigue | 1 | 2019 | 1550 | 0.100 |
Why?
|
Disease-Free Survival | 2 | 2019 | 6817 | 0.100 |
Why?
|
Medical Oncology | 2 | 2022 | 2316 | 0.090 |
Why?
|
Education, Medical, Undergraduate | 1 | 2020 | 1071 | 0.090 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2021 | 2054 | 0.090 |
Why?
|
Surgical Procedures, Operative | 1 | 2022 | 1923 | 0.090 |
Why?
|
Attitude | 1 | 2015 | 772 | 0.090 |
Why?
|
Health Personnel | 1 | 2024 | 3335 | 0.090 |
Why?
|
Age Distribution | 1 | 2016 | 2873 | 0.090 |
Why?
|
Sex Factors | 2 | 2021 | 10552 | 0.080 |
Why?
|
Palliative Care | 2 | 2023 | 3593 | 0.080 |
Why?
|
Syndrome | 1 | 2015 | 3269 | 0.080 |
Why?
|
Dendritic Cells | 1 | 2020 | 2726 | 0.080 |
Why?
|
Risk Factors | 6 | 2024 | 74219 | 0.080 |
Why?
|
Time Factors | 2 | 2021 | 39953 | 0.080 |
Why?
|
Tomography, X-Ray Computed | 2 | 2024 | 20600 | 0.080 |
Why?
|
Severity of Illness Index | 3 | 2020 | 15845 | 0.070 |
Why?
|
Diet, Fat-Restricted | 1 | 2010 | 329 | 0.070 |
Why?
|
Attitude to Health | 1 | 2016 | 2024 | 0.070 |
Why?
|
Neoplasm Staging | 2 | 2019 | 11118 | 0.070 |
Why?
|
Hematologic Neoplasms | 1 | 2019 | 1895 | 0.070 |
Why?
|
Quality of Life | 3 | 2020 | 13362 | 0.070 |
Why?
|
Medicaid | 1 | 2020 | 2814 | 0.070 |
Why?
|
Blood Pressure Determination | 1 | 2010 | 633 | 0.070 |
Why?
|
Prevalence | 1 | 2023 | 15717 | 0.070 |
Why?
|
Treatment Outcome | 4 | 2021 | 64670 | 0.070 |
Why?
|
Motivation | 1 | 2015 | 2003 | 0.060 |
Why?
|
Odds Ratio | 1 | 2017 | 9648 | 0.060 |
Why?
|
Fruit | 1 | 2010 | 1158 | 0.060 |
Why?
|
Vegetables | 1 | 2010 | 1192 | 0.060 |
Why?
|
Young Adult | 6 | 2020 | 59199 | 0.060 |
Why?
|
Disease Progression | 1 | 2021 | 13506 | 0.060 |
Why?
|
Lung | 1 | 2022 | 9979 | 0.060 |
Why?
|
Child, Preschool | 3 | 2020 | 42217 | 0.050 |
Why?
|
Infant, Newborn | 2 | 2020 | 26187 | 0.050 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2014 | 3493 | 0.050 |
Why?
|
Blister | 1 | 2023 | 86 | 0.050 |
Why?
|
Viral Load | 2 | 2023 | 3328 | 0.050 |
Why?
|
Multivariate Analysis | 1 | 2016 | 12058 | 0.050 |
Why?
|
Pregnancy | 1 | 2024 | 29872 | 0.050 |
Why?
|
Dermatitis | 1 | 2024 | 202 | 0.050 |
Why?
|
Intranuclear Inclusion Bodies | 1 | 2022 | 34 | 0.050 |
Why?
|
Adolescent | 5 | 2020 | 88271 | 0.050 |
Why?
|
Infant | 2 | 2020 | 36164 | 0.050 |
Why?
|
Neoplasm Invasiveness | 2 | 2021 | 3591 | 0.050 |
Why?
|
Emergency Service, Hospital | 1 | 2020 | 7873 | 0.050 |
Why?
|
Biological Therapy | 1 | 2022 | 139 | 0.050 |
Why?
|
Databases, Factual | 1 | 2016 | 7969 | 0.050 |
Why?
|
Child | 4 | 2020 | 80134 | 0.040 |
Why?
|
United States | 6 | 2021 | 72337 | 0.040 |
Why?
|
Vitiligo | 1 | 2020 | 96 | 0.040 |
Why?
|
Tacrolimus | 1 | 2023 | 735 | 0.040 |
Why?
|
Delphi Technique | 1 | 2023 | 849 | 0.040 |
Why?
|
Italy | 1 | 2021 | 843 | 0.040 |
Why?
|
Follow-Up Studies | 1 | 2020 | 39121 | 0.040 |
Why?
|
New York City | 1 | 2021 | 730 | 0.040 |
Why?
|
Curriculum | 2 | 2023 | 3739 | 0.040 |
Why?
|
Risk | 1 | 2010 | 9614 | 0.040 |
Why?
|
New York | 1 | 2020 | 875 | 0.040 |
Why?
|
Postoperative Period | 1 | 2022 | 1818 | 0.040 |
Why?
|
Interleukin-12 | 1 | 2020 | 578 | 0.040 |
Why?
|
Head | 1 | 2023 | 922 | 0.040 |
Why?
|
Antibody Formation | 1 | 2022 | 1391 | 0.040 |
Why?
|
Pruritus | 1 | 2020 | 378 | 0.040 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2021 | 4574 | 0.030 |
Why?
|
Prospective Studies | 2 | 2022 | 54419 | 0.030 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2021 | 736 | 0.030 |
Why?
|
Hospitalists | 1 | 2020 | 294 | 0.030 |
Why?
|
Interleukin-4 | 1 | 2020 | 1154 | 0.030 |
Why?
|
Cytokines | 2 | 2021 | 7386 | 0.030 |
Why?
|
Advisory Committees | 1 | 2020 | 788 | 0.030 |
Why?
|
Frontal Lobe | 1 | 2022 | 1417 | 0.030 |
Why?
|
Physician Executives | 1 | 2015 | 134 | 0.030 |
Why?
|
Interdisciplinary Communication | 1 | 2020 | 928 | 0.030 |
Why?
|
Streptavidin | 1 | 2014 | 81 | 0.030 |
Why?
|
Needs Assessment | 1 | 2020 | 1139 | 0.030 |
Why?
|
SEER Program | 1 | 2019 | 1450 | 0.030 |
Why?
|
Tumor Burden | 1 | 2020 | 1892 | 0.030 |
Why?
|
Sirolimus | 1 | 2021 | 1540 | 0.030 |
Why?
|
Kaplan-Meier Estimate | 1 | 2024 | 6482 | 0.030 |
Why?
|
Health Care Surveys | 1 | 2020 | 2424 | 0.030 |
Why?
|
Attitude of Health Personnel | 2 | 2019 | 3882 | 0.030 |
Why?
|
Disease Susceptibility | 1 | 2020 | 1790 | 0.030 |
Why?
|
Biotin | 1 | 2014 | 251 | 0.030 |
Why?
|
Disease Outbreaks | 1 | 2022 | 1747 | 0.030 |
Why?
|
Mice, Inbred C57BL | 2 | 2021 | 22129 | 0.030 |
Why?
|
Host-Pathogen Interactions | 1 | 2021 | 1448 | 0.030 |
Why?
|
Antibodies, Neutralizing | 1 | 2022 | 1935 | 0.020 |
Why?
|
Inflammation Mediators | 1 | 2021 | 1885 | 0.020 |
Why?
|
Antigens, Neoplasm | 1 | 2020 | 1984 | 0.020 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2021 | 2057 | 0.020 |
Why?
|
Hypoglycemic Agents | 1 | 2024 | 3086 | 0.020 |
Why?
|
Interferon-gamma | 1 | 2020 | 3155 | 0.020 |
Why?
|
Colonoscopy | 1 | 2019 | 1398 | 0.020 |
Why?
|
Risk Reduction Behavior | 1 | 2018 | 1111 | 0.020 |
Why?
|
Leadership | 1 | 2020 | 1386 | 0.020 |
Why?
|
Antibodies, Viral | 1 | 2022 | 3149 | 0.020 |
Why?
|
Vaccination | 1 | 2022 | 3368 | 0.020 |
Why?
|
Hypertension | 1 | 2010 | 8537 | 0.020 |
Why?
|
Ambulatory Care | 1 | 2020 | 2769 | 0.020 |
Why?
|
Mice | 3 | 2021 | 81324 | 0.020 |
Why?
|
Calcium-Binding Proteins | 1 | 2014 | 1066 | 0.020 |
Why?
|
Inpatients | 1 | 2021 | 2545 | 0.020 |
Why?
|
Hematopoietic Stem Cells | 1 | 2021 | 3388 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2019 | 4908 | 0.020 |
Why?
|
Mice, Transgenic | 1 | 2021 | 9518 | 0.020 |
Why?
|
Societies, Medical | 1 | 2020 | 3923 | 0.020 |
Why?
|
Massachusetts | 1 | 2021 | 8836 | 0.020 |
Why?
|
Molecular Targeted Therapy | 1 | 2019 | 2813 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2019 | 8519 | 0.020 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2021 | 3092 | 0.020 |
Why?
|
Cause of Death | 1 | 2018 | 3688 | 0.020 |
Why?
|
Communication | 1 | 2020 | 3852 | 0.020 |
Why?
|
Antibodies | 1 | 2014 | 2415 | 0.020 |
Why?
|
Cell Proliferation | 1 | 2021 | 10421 | 0.020 |
Why?
|
Cells, Cultured | 1 | 2021 | 18926 | 0.020 |
Why?
|
Survival Analysis | 1 | 2018 | 10083 | 0.020 |
Why?
|
Apoptosis | 1 | 2021 | 9478 | 0.020 |
Why?
|
HEK293 Cells | 1 | 2014 | 4250 | 0.020 |
Why?
|
Early Detection of Cancer | 1 | 2019 | 3196 | 0.020 |
Why?
|
Delivery of Health Care | 1 | 2023 | 5333 | 0.020 |
Why?
|
Animals | 3 | 2021 | 168083 | 0.010 |
Why?
|
Mass Screening | 1 | 2019 | 5425 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2021 | 22157 | 0.010 |
Why?
|
Telemedicine | 1 | 2020 | 3051 | 0.010 |
Why?
|
DNA | 1 | 2014 | 7189 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2014 | 16947 | 0.010 |
Why?
|